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Increasing life expectancy is causing the prevalence of age-related diseases to rise, and there is an 
urgent need for new strategies to improve health at older ages. Reduced activity of insulin/insulin-like 
growth factor signaling (IIS) and mechanistic target of rapamycin (mTOR) nutrient-sensing signaling 
network can extend lifespan and improve health during aging in diverse organisms. However, the 
extensive feedback in this network and adverse side-effects of inhibition imply that simultaneous 
targeting of specific effectors in the network may most effectively combat the effects of aging. We 
show that the mitogen-activated protein kinase kinase (MEK) inhibitor trametinib, the mTOR complex 
1 (mTORC1) inhibitor rapamycin, and the glycogen synthase kinase-3 (GSK-3) inhibitor lithium act 
additively to increase longevity in Drosophila. Remarkably, the triple drug combination increased 
lifespan by 48%. Furthermore, the combination of lithium with rapamycin cancelled the latter’s effects 
on lipid metabolism. In conclusion, a polypharmacology approach of combining established, pro-
longevity drug inhibitors of specific nodes may be the most effective way to target the nutrient-sensing 
network to improve late-life health.  
 













Aging is a complex process of progressive cell, tissue and systemic dysfunction that is involved in the 
etiology of age-related diseases (1). Genetic, dietary and pharmacological interventions can 
ameliorate the effects of aging in laboratory animals and may lead to therapies against age-related 
diseases in humans (2–4).  
 
In organisms ranging from invertebrates to mammals, reducing the activity of the nutrient-sensing 
mTOR and insulin/IGF signaling (IIS) network can promote longevity and health during aging (2, 3). 
Lowering network activity can also protect against the pathology associated with genetic models of 
age-related diseases (1, 2). The network contains many drug targets, including mTOR, MEK and 
GSK-3 (Fig. 1A). Down-regulation of mTOR activity by rapamycin, GSK-3 by lithium, or MEK by 
trametinib can each individually extend lifespan in laboratory organisms (5–11), and brief inhibition of 
mTOR has recently been shown to increase the response of elderly people to immunization against 
influenza (12). In addition, both mTOR and MEK inhibitors have shown to reduce senescent 
phenotypes in human cells (13), while lithium levels in drinking water correlate with reduced all-cause 
mortality in a Japanese population (10). An advantage of pharmacological interventions is that the 
timing and dose of drug administration are relatively simple to optimize, and drugs can be easily 
combined (4, 14–16). Combination drug treatments also have the potential to counter resistance from 
feedback and to reduce each other’s side-effects (17). Rapamycin, trametinib and lithium each target 
different kinases and transcription factors to extend lifespan (5, 8, 11), and therefore their effector 
mechanisms are therefore at least partially different from each other. Simultaneous inhibition of 
multiple targets within the nutrient-sensing network may hence be needed to optimize effector outputs 
and health benefits. Here, we measure the effects of combination treatments of rapamycin, lithium and 
trametinib on lifespan and other traits, using Drosophila as a model organism. 
 
RESULTS AND DISCUSSION 
Rapamycin treatment, from C. elegans to humans, is associated with altered metabolism, including 
hypertriglyceridemia and obesity (5, 18). Alone, a lifespan-extending dose of lithium (11) did not alter 
triglyceride levels, but simultaneous treatment with both lithium and rapamycin reversed the 
dyslipidemia caused by rapamycin (Fig. 1B). To confirm that this change in lipid levels was 
physiologically relevant, we pre-treated (14d) flies with lithium, rapamycin or a combination, and 
assessed their survival under starvation. Lithium did not alter survival under starvation conditions, 
while rapamycin increased it (Fig. 1C). Consistent with their effects on lipid levels, combining lithium 
and rapamycin treatment resulted in control levels of starvation resistance (Fig. 1C). Lithium can 
therefore reverse metabolic storage alterations associated with mTOR inhibition. 
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Lithium inhibits GSK-3 activity to extend lifespan (11), implying that activation of GSK3 is likely, if 
anything, to shorten lifespan. Inhibition of IIS in the canonical PI3K pathway can extend lifespan and 
healthspan, but reduces inhibitory phosphorylation of GSK3 by Akt (Fig. 1A), and hence activates 
GSK3 (4), a potentially deleterious side-effect of lowered IIS (19). We therefore tested whether lithium 
could have additive effects in combination with genetic inhibition of IIS upstream of Akt. Lithium was 
able to further extended the lifespan of flies lacking the insulin-like peptides 2, 3 and 5 (dilp2-3,5) (Fig. 
1D) (20). In contrast, rapamycin or trametinib, neither of which inhibit GSK3, were not able to extend 
the lifespan of dilp2-3,5 flies (Fig. 1E-F). Lithium thus reverses an adverse side-effect of inhibition of 
the canonical IIS pathway.   
 
Because rapamycin, lithium and trametinib extend lifespan by at least partially independent 
mechanisms, we investigated the effects on lifespan of their double and triple combinations. Double 
combinations of lithium and rapamycin, lithium and trametinib, or rapamycin and trametinib produced 
a reproducibly greater lifespan extension than controls, on average 30%, compared to each 
compound alone, which extended lifespan by an average of 11% (Fig. 2A-B). Importantly, the triple 
combination of rapamycin, trametinib and lithium promoted longevity beyond that of the double 
combinations, extending median lifespan by 48% (Fig. 2A-B). Thus, each compound independently 
displayed an additive effect on lifespan. The additive effect of rapamycin, trametinib and lithium on 
lifespan is unlikely to have been due to changes in feeding behavior, because feeding frequency, food 
intake, and drug uptake were unaltered by the treatment regimens (Fig. 2C-D). Fecundity is often 
reduced in interventions that promote lifespan extension (21), and this could provide a potential 
explanation for the greater longevity with drug combinations. However, at the concentrations used, 
only trametinib and combinations containing trametinib significantly reduced fecundity (Fig. 2E). 
Importantly, the triple drug combination did not reduce egg-laying below that achieved with double 
trametinib-containing combinations, or trametinib treatment alone (Fig. 2E). Thus, a trade-off with 
fecundity is unlikely to explain the greater longevity observed with the triple drug combination.  
 
Given the complex nature of the aging process, it is unlikely that the most effective preventative anti-
aging therapy could be achieved by a single compound with a single target. We have shown that 
simultaneous inhibition by three components of different nodes in the nutrient-sensing network using a 
combination of drugs already approved for human use is a viable strategy to maximize animal 
longevity and to reduce a side-effect. Rapamycin treatment results in insulin-resistance and 
dyslipidemia in patients and mice (4, 18, 22), and this disturbance manifests as hypertriglyceridemia in 
Drosophila (5). Lithium reversed this and the starvation resistance associated with rapamycin 
treatment. Taken together, our results highlight a potential therapeutic avenue to promote longevity, 
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co-administrating compounds that act on different nodes of the nutrient-sensing network, to maximize 





Fly stocks, husbandry, and lifespan analysis: For all experiments, a wild type white Dahomey 
(wDah) stock, or when noted dilp2-3,5 mutant flies (wDah backcrossed) were used, and raised as 
previously described (20).  LiCl (Sigma) in ddH2O, Trametinib (LC laboratories) in DMSO, and 
Rapamycin (LC laboratories) in 100% ethanol, were added to SYA medium to a final concentration of 
1mM, 15.6μM, and 50μM, respectively (5, 8, 11). Equivalent volumes and concentrations of vehicle 
were added to SYA medium for control treatments. Drug treatments were started 2 days post-
eclosion. Lifespan analysis: Female flies (n=130-200, 15-20/vial) were sorted on to SYA medium that 
was replaced every 2-3 days throughout life. Lifespan data are available under the doi ####. 
Starvation assay was performed as previously described (11). 
Food intake, fecundity, and triglyceride measurements: Feeding behavior (proboscis extension at 
1 and 15 days of treatment) and food intake (quantified by dye-calibrated feeding) (4-5 flies/replicate, 
n=8-10) were measured as previously described (23). Fecundity was quantified as # of eggs laid 
within 24h (15d) and triglyceride measurements (5 flies/replicate, n=8) were performed as previously 
described (5, 11).  
Mass spectrometry: Flies (n=5, 15 flies) were treated with drugs (15d), their digestive system 
allowed to void (1h), snap frozen, drugs extracted as previously described (5), and resuspended in 
100µl acetonitrile/isopropanol 70:30 for measurement with an Acquitiy UPLCTM I-class System/Xevo 
TQ-S (Waters) with MassLynx and absolute quantification.  
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Figure 1. Lithium blocks negative side-effects of mTORC1 and IIS inhibition. 
A simplified diagram of the Drosophila nutrient-sensing network showing the target kinases of 
rapamycin, trametinib and lithium (A). Lithium reversed the (B) hypertriglyceridemia (n=6 replicas of 5 
flies per condition, 1-way ANOVA) and starvation resistance (C) induced by rapamycin (50µM) (n=75). 
Lithium treatment significantly extended lifespan of both wDah and dilp2-3,5 mutant flies (D). Neither 
rapamycin (E; p=0.58) nor trametinib (F; p=0.14) further extended lifespan of dilp2-3,5 mutant flies 
(log-rank test (n=150)). Cox Proportional Hazard analysis showed a significant genotype by 
treatment interaction for rapamycin (p=0.002) and trametinib (p=0.0018). Error bars represent SEM. 
*** p<0.001 (1-way ANOVA or log-rank test). 
 
Figure 2. A triple drug combination maximizes longevity.  
(A) Representative survival curve and associated pairwise log-rank tests. (B) Replicated median/max. 
lifespans plotted for all single (n=4), double (n=3), and triple (n=2) combinations of rapamycin, 
trametinib and lithium treatments. Each lifespan contained 130-200 flies per treatment. Numbers in 
parentheses show (total number of flies/number of censors). (C) Proboscis extension feeding behavior 
assay (1 and 15 days of treatment) and quantification of ingested non-absorbable (bottom) blue dye 
(n=8 replicas of 4-5 flies 15d old, 1-way ANOVA with Dunnett's test). Mass spectrometry of systemic 
trametinib (top) or rapamycin (bottom) levels when other drugs were co-administered (D) (n=5, 1-way 
ANOVA). Fecundity of treated (15d) flies within a 24h period (n=8 replicas of 4-5 flies) (E). Error bars 
show Tukey whiskers and outlying data points are shown as dots.  * p<0.05, ** p<0.01, *** p<0.001 
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